Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, McNeill M, Amaravadi L, Sweetser M, et al. Lancet Neurol. 2014 Mar 18. PMID: 24656609. Abstract CommentRecommendBookmarkWatch